ProfileGDS5678 / 1438731_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 70% 70% 69% 71% 70% 74% 70% 68% 67% 69% 68% 71% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3363670
GSM967853U87-EV human glioblastoma xenograft - Control 24.3634970
GSM967854U87-EV human glioblastoma xenograft - Control 34.3309370
GSM967855U87-EV human glioblastoma xenograft - Control 44.3296569
GSM967856U87-EV human glioblastoma xenograft - Control 54.418871
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.32870
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7322174
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3437570
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1839768
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0890567
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2683569
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1759268
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4682971
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3479170